Our talk will review current pharmacologic modalities for acute pain — including opioids, NSAIDs, and adjuvants — covering mechanisms, limitations, and recent literature, before pivoting to the emerging field of selective sodium channel blockade. The centerpiece is a focused review of Nav1.8 as a peripheral nociceptor-specific target and suzetrigine (JOURNAVX™), the first new non-opioid analgesic class in over 25 years, including Phase 3 trial data, safety profile, and the future of Nav-targeted...
